Skip to content

MEDIATOR INFORMATION

Focus on the compensation

On 31 October 2022, 4,179 patients received offers of compensation for a total amount of 236 million Euros, 202.8 million of which have already been paid.

For any information about Mediator, please call the Medical Information Department at the following number: +33 1 55 72 60 00


MEDIATOR

News

MEDIATOR

Press

2019
On 18 April 2019, the Court announced that the Mediator trial would be held from 23 September 2019 for a period of 6 months.
2018
Announcement of the beginning of the trial (from September 2019) by the Paris Criminal Court.
2017
Referral order for Servier to appear before the Criminal Court.
2016
State’s responsibility confirmed in the Mediator case.
2015
Investigation resumes, considered incomplete by the Investigation Chamber.
2014
Death of Doctor Jacques Servier, Olivier Laureau appointed President of Servier Group.
2013
ANSM (National Drug Agency) indicted (previously Afssaps) for “manslaughter and unintentional injury”.
2012
Servier indicted for “manslaughter and unintentional injury”.
2011
The IGAS (General Inspection of Social Affairs) report is handed to the Minister of Health. Opening of two legal investigations brought against X for “deception and unlawful acquisition of an interest” and “manslaughter”. Servier proposes the setting up of a compensation fund for patients. Creation of a compensation fund managed by ONIAM (French National Office for Compensation for Medical Accidents) Indictment of Doctor Jacques Servier and 5 Servier companies for “deception and fraud”
2010
Afssaps estimates the number of Mediator®-related deaths to be 500.
2009
The National Pharmacovigilance Committee identifies and validates the signal of valvulopathies in patients treated with Mediator. The CAMM (Marketing Authorisation Committee) concludes that Benfluorex has a negative benefit-risk ratio. Suspension of the marketing authorisation of Mediator® and its generics by AFSSAPS.
2008
AFSSAPS authorises the marketing of two generics of Mediator®.
2007
The Marketing Authorisation Committee reassesses the benefit-risk ratio of Mediator® and proposes a change in the indications.
2005
According to the National Pharmacovigilance Committee, the number of cases of pulmonary arterial hypertension does not constitute a significant signal of the toxicity of Mediator®. 2005-2009: Servier carries out a study of the efficacy and safety of Mediator® in diabetic patients.
2003
Servier stops marketing Mediator® in Spain and in Italy for commercial and industrial reasons. Publication of a case of valvulopathy in Spain.
2001
In response to the European health agency’s request, Servier proposes a study protocol on Mediator® to the Italian and French authorities.
1999
First cases of aortic valvulopathy and pulmonary arterial hypertension in two patients treated with Mediator®.
1998
Official pharmacovigilance investigation of Mediator® initiated by AFSSAPS (French Agency for the Safety of Health Products) – Opening of the European investigation.
1974
Mediator® obtains Marketing Authorisation.

Press contact

presse@servier.com